Real-world data suggests that adding CGRP inhibitors to onabotulinumtoxinA adds efficacy

Preliminary data on the use of anti-CGRP mAbs in pediatric migraineПодробнее

MIGRAINE PREVENTION IN THE REAL WORLD: EXPLORING THE ROLE OF ANTI-CGRP ANTIBODIESПодробнее

Combination treatment with CGRP mAbs and onabotulinumtoxinA for chronic migraine controlПодробнее

Real-world data on anti-CGRP monoclonal antibodiesПодробнее

Observational Study comparing Anti-CGRP mABs to OnabotulinumtoxinA for #chronicmigraineПодробнее

CGRP Inhibitors as Preventative Migraine TherapyПодробнее

Comparing CGRP ligand- and receptor-directed antibody treatments in migraineПодробнее

Fred Cohen, MD: Combined Use of CGRP Medications and OnabotulinumtoxinA in MigraineПодробнее

New Data Shows Delay in Anti-CGRP Medication Response for SomeПодробнее

Is the CGRP ligand or receptor a better target in migraine?Подробнее

How real-world data generation can assist biosimilar implementationПодробнее

Real-world studies of CGRP monoclonal antibodies and gepants for migraineПодробнее

Effect of CGRP Inhibitors on Patients With Cluster HeadachesПодробнее

Migraine prevention in the real world: Exploring the role of anti-CGRP antibodiesПодробнее

Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination TreatmentПодробнее

CGRP monoclonal antibody use in JapanПодробнее